ccs_chart

Many IVF programs are still relying heavily on judging an embryo’s potential to implant by how it looks under the microscope – essentially judging a book by its cover. But at RMANJ, our evidence-based approach demands we do more.

RMANJ led the development of a one-of-a-kind, well validated, 24-chromosome screening process called SelectCCS which safely identifies whether embryos have a normal number of chromosomes (euploidy) or an abnormal number of chromosomes (aneuploidy). Since we now know genetic errors can occur with all 23 pairs of chromosomes, our screening process is comprehensive by counting all chromosomes at the molecular level and more accurate than previous testing processes that only count a handful of chromosomes.

Current data suggests that 50-70% of miscarriages are due to embryos with too few or too many chromosomes. At the same time we know that the frequency of aneuploidy increases with age. Using a more comprehensive and evidence-based approach like SelectCCS during the embryo selection process can improve safety and efficacy of your IVF cycle. SelectCCS has demonstrated to be 98% accurate in determining aneuploidy2,3.

SelectCCS also makes the promise of single embryo transfer (SET) a reality, providing uncompromising success rates without complications often associated with twin pregnancies and deliveries.

“Advances in screening technology that allow us to rapidly and safely determine if an embryo is chromosomally normal now make ‘SET’ a more viable pathway to pregnancy for couples undergoing IVF. We can reduce the risk of twins, which tend to be more complicated pregnancies, but thanks to improved freezing technology not reduce the chance of having two children if that’s what a couple wants in the long run.” 

Eric J. Forman, MD, FACOG, BEST Trial Investigator

Learn how SET can make the promise of “one embryo, one healthy baby” a reality.

In 2013 RMANJ donated SelectCCS to the Foundation for the Assessment and Enhancement of Embryonic Competence (FAEEC), a non-profit organization dedicated to improving outcomes and advancing knowledge in the areas of research, diagnosis, and education. SelectCCS is owned and operated by the Foundation for the Assessment and Enhancement of Embryonic Competence (www.faeec.org).

1. Scott RT, Jr., Upham K, Forman E, Hong K, Scott K, Taylor D, Tao X, Treff NR. Blastocyst biopsy with comprehensive chromosome screening and fresh embryo transfer significantly increases in vitro fertilitzation implantation and delivery rates; a randomized controlled trial. Fertil Steril 2013. In Press.

2. Richard T. Scott Jr., M.D., Kathleen Ferry, B.S., Jing Su, M.S., Xin Tao, M.S., Katherine Scott, M.S., and Nathan R. Treff, Ph.D. Comprehensive chromosome screening is highly predictive of the reproductive potential of human embryos: a prospective, blinded, nonselection study. Fertility and Sterility. April 2012; 97(4):870-5.

3.Forman, E.J., Tao, X., Ferry, K.M., Taylor, D., Treff, N.R., Scott, R.T. Single Embryo Transfer with Comprehensive Chromosome Screening Results in Improved Ongoing Pregnancy Rates and Decreased Miscarriage Rates. Human Reproduction. April 2012; 27(4):1217-22.

Please note that a comparison of clinic success rates may not be meaningful because a patient’s medical characteristics, treatment approaches and entrance criteria for ART may vary from clinic to clinic. We encourage you to learn more at www.sart.org.